Ariana Pelosci

Findings from a pooled analysis indicated that reductions in ctDNA were associated with improved clinical benefit across multiple end points in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.

Results from a phase 2 study highlighted a tolerable safety profile when patients with mismatch repair proficient endometrial cancer were treated with avelumab plus talazoparib.

Superior survival were observed across all efficacy outcomes for patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel compared with standard of care.

Patients undergoing complex oncologic surgery for head and neck cancer appeared to have shorter hospital stays when using a multiprofessional assessment and information day compared with those who did not.

Results from a phase 3 trial show similar results in regard to overall survival when patients with advanced pancreatic ductal adenocarcinoma were treated with either folinic acid, fluorouracil, irinotecan, oxaliplatin or gemcitabine/nab-paclitaxel in the first line.

Overall survival was significantly improved when elotuzumab was added to pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with lenalidomide and proteasome inhibitors

The phase 1/2 Neo-PATH trial show promising pathological complete response rates and moderate toxicity in patients with stage III or III ERBB2-positive breast cancer when treated with pertuzumab, atezolizumab, trastuzumab, and docetaxel.

Investigators highlighted that when determining a treatment strategy for patients with early-stage prostate cancer, baseline benign prostate hyperplasia symptoms should be taken into consideration.

Results from the phase 3 ICON8 trial showed patients with epithelial ovarian cancer did not experience an overall survival or progression-free survival benefit with weekly dose-dense chemotherapy in the first line compared with 3 times weekly.

Results from a pre-specified interim analysis of the phase 3 KarMMa-3 trial showed the primary end point of progression-free survival was met following treatment with idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma following 2 to 4 previous lines of therapy and who were refractory to their last treatment.

Patients who carry MSH2 and MSH6 variants were more likely to be diagnosed with prostate cancer compared with noncarriers.

Results from the phase 3 ASCEMBL trial led to the approval of asciminib by the European Commission for patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

In light of the recent FDA approval of darolutamide plus docetaxel and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer, E. David Crawford, MD, discussed the research that paved the way for the regulatory decision and where future efforts need to be focused.

Long-term follow-up data of abivertinib for patients with EGFR T70M–mutated advanced non–small cell lung cancer highlighted promising responses.

Investigators stated that comprehending the quality of life reduction associated with MRI with or without mammography for patients with ductal carcinoma in situ may help to improve patient experience and help in the development of targeted strategies.

Patients with BRAF V600–mutated melanoma with central nervous system metastases had positive intracranial activity following treatment with atezolizumab, vemurafenib, and cobimetinib.

Based on results of the phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for pediatric patients with chronic graft-versus-host disease.

Results from a multicenter study showed similar median overall survival results with laser interstitial thermal therapy compared with other tumor resection studies that used radiation and chemotherapy followed by laser ablation in patients with IDH wild-type glioblastoma.

Trevor M. Feinstein, MD, discussed the phase 3 DUBLIN-3 trial evaluating docetaxel with or without plinabulin for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer.

A real-world, prospective cohort study identified independent predictors may increase the risk of early mortality in patients with newly diagnosed multiple myeloma.

Results from the phase 1/2 ARROW trial showed robust and durable responses in patients with RET fusion–positive cancer treated with pralsetinib.

Based on results from the phase 3 MOMENTUM trial, the FDA has accepted a new drug application of momelotinib for patients with myelofibrosis.

Pediatric and adult patients who have β -thalassemia and need regular red blood cell infusions may now receive betibeglogene autotemcel, which has been approved by the FDA.

Findings from a recent study show that a neutrophil-to-lymphocyte ratio of less than 6 before treatment was correlated with improved overall survival for patients with endometrial cancer.

Results from the second interim analysis of the phase 3 TROPiCS-02 trial showed significantly improved overall survival among patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were given sacituzumab govitecan vs physician’s choice of treatment.

Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.

The primary end point of improved progression-free survival was met in the phase 3 DESTINY-Breast02 trial when patients with HER2-positive unresectable and/or metastatic breast cancer were given trastuzumab deruxtecan vs physician’s choice of therapy.

Regular approval has been granted to capmatinib for the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation.

At ASCO 2022, Roy S. Herbst, MD, PhD, reviews a substudy of the phase 2 Lung-MAP trial which investigates ramucirumab plus pembrolizumab for patients with advanced non–small cell lung cancer who demonstrated resistance to previous immunotherapy.

Elacestrant was granted priority review by the FDA for the treatment of estrogen receptor–positive, HER2-negative metastatic breast cancer.